Stéphane Bancel, CEO of Moderna, has expressed serious concerns about Europe’s preparedness for potential bioterrorism and pandemics. He highlighted that while the world has improved its manufacturing capabilities since COVID-19, Europe lacks a significant mRNA production base. This absence poses a risk if a health crisis were to emerge on the continent, as there would be no local capacity to respond effectively.
Bancel pointed out that the closure of BioNTech’s manufacturing sites in Germany has left Europe vulnerable. He advocates for partnerships with European governments to establish mRNA facilities, similar to those in Canada and the UK. This move is crucial for ensuring that Europe can respond swiftly to future health threats.
In addition to pandemic preparedness, Moderna is diversifying its portfolio beyond COVID-19 vaccines. The company is focusing on treatments for various diseases, including cancer, which could help stabilize its financial outlook. Bancel believes that by leveraging mRNA technology, Moderna can contribute significantly to healthcare advancements.
As Moderna shifts back to its original mission, the implications of these developments extend beyond the company itself. They highlight the urgent need for Europe to bolster its biopharmaceutical infrastructure to safeguard public health against future threats.
Source: Euronews
